- Home
- VRNS vs SRRK Comparison
VRNS vs SRRK Comparison
Compare VRNS & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | SRRK |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.6B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VRNS | SRRK |
|---|---|---|
| Price | $34.90 | $46.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 11 |
| Target Price | ★ $57.55 | $49.80 |
| AVG Volume (30 Days) | ★ 2.0M | 1.0M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $608,677,000.00 | N/A |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $15.80 | $20,271.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.37 | N/A |
| 52 Week Low | $30.02 | $22.71 |
| 52 Week High | $63.90 | $48.28 |
Technical Indicators
Market Signals| Indicator | VRNS | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 58.72 |
| Support Level | $34.06 | $40.63 |
| Resistance Level | $35.89 | $44.50 |
| Average True Range (ATR) | 1.14 | 2.09 |
| MACD | 0.36 | -0.18 |
| Stochastic Oscillator | 66.92 | 84.63 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.